Base de dados : MEDLINE
Pesquisa : D02.241.081.114.500.350.900 [Categoria DeCS]
Referências encontradas : 1530 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 153 ir para página                         

  1 / 1530 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29396367
[Au] Autor:Police A; Shankar VK; Narasimha Murthy S
[Ad] Endereço:Department of Pharmaceutics and Drug Delivery, University of Mississippi, MS 38677, USA.
[Ti] Título:RP-HPLC method for simultaneous estimation of vigabatrin, gamma-aminobutyric acid and taurine in biological samples.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;1076:44-53, 2018 Feb 15.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Vigabatrin is used as first line drug in treatment of infantile spasms for its potential benefit overweighing risk of causing permanent peripheral visual field defects and retinal damage. Chronic administration of vigabatrin in rats has demonstrated these ocular events are result of GABA accumulation and depletion of taurine levels in retinal tissues. In vigabatrin clinical studies taurine plasma level is considered as biomarker for studying structure and function of retina. The analytical method is essential to monitor taurine levels along with vigabatrin and GABA. A RP-HPLC method has been developed and validated for simultaneous estimation of vigabatrin, GABA and taurine using surrogate matrix. Analytes were extracted from human plasma, rat plasma, retina and brain by simple protein precipitation method and derivatized by naphthalene 2, 3­dicarboxaldehyde to produce stable fluorescent active isoindole derivatives. The chromatographic analysis was performed on Zorbax Eclipse AAA column using gradient elution profile and eluent was monitored using fluorescence detector. A linear plot of calibration curve was observed in concentration range of 64.6 to 6458, 51.5 to 5150 and 62.5 to 6258 ng/mL for vigabatrin, GABA and taurine, respectively with r ≥ 0.997 for all analytes. The method was successfully applied for estimating levels of vigabatrin and its modulator effect on GABA and taurine levels in rat plasma, brain and retinal tissue. This RP-HPLC method can be applied in clinical and preclinical studies to explore the effect of taurine deficiency and to investigate novel approaches for alleviating vigabatrin induced ocular toxicity.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Taurina/análise
Vigabatrina/análise
Ácido gama-Aminobutírico/análise
[Mh] Termos MeSH secundário: Animais
Química Encefálica
Cromatografia de Fase Reversa/métodos
Seres Humanos
Modelos Lineares
Masculino
Ratos
Ratos Sprague-Dawley
Reprodutibilidade dos Testes
Retina/química
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
1EQV5MLY3D (Taurine); 56-12-2 (gamma-Aminobutyric Acid); GR120KRT6K (Vigabatrin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180204
[St] Status:MEDLINE


  2 / 1530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28857179
[Au] Autor:Androsova G; Krause R; Borghei M; Wassenaar M; Auce P; Avbersek A; Becker F; Berghuis B; Campbell E; Coppola A; Francis B; Wolking S; Cavalleri GL; Craig J; Delanty N; Koeleman BPC; Kunz WS; Lerche H; Marson AG; Sander JW; Sills GJ; Striano P; Zara F; Sisodiya SM; Depondt C; EpiPGX Consortium
[Ad] Endereço:Luxembourg Center for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
[Ti] Título:Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis.
[So] Source:Epilepsia;58(10):1734-1741, 2017 Oct.
[Is] ISSN:1528-1167
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) is a common epilepsy syndrome that is often poorly controlled by antiepileptic drug (AED) treatment. Comparative AED effectiveness studies in this condition are lacking. We report retention, efficacy, and tolerability in a cohort of patients with MTLE-HS. METHODS: Clinical data were collected from a European database of patients with epilepsy. We estimated retention, 12-month seizure freedom, and adverse drug reaction (ADR) rates for the 10 most commonly used AEDs in patients with MTLE-HS. RESULTS: Seven hundred sixty-seven patients with a total of 3,249 AED trials were included. The highest 12-month retention rates were observed with carbamazepine (85.9%), valproate (85%), and clobazam (79%). Twelve-month seizure freedom rates varied from 1.2% for gabapentin and vigabatrin to 11% for carbamazepine. Response rates were highest for AEDs that were prescribed as initial treatment and lowest for AEDs that were used in a third or higher instance. ADRs were reported in 47.6% of patients, with the highest rates observed with oxcarbazepine (35.7%), topiramate (30.9%), and pregabalin (27.4%), and the lowest rates with clobazam (6.5%), gabapentin (8.9%), and lamotrigine (16.6%). The most commonly reported ADRs were lethargy and drowsiness, dizziness, vertigo and ataxia, and blurred vision and diplopia. SIGNIFICANCE: Our results did not demonstrate any clear advantage of newer versus older AEDs. Our results provide useful insights into AED retention, efficacy, and ADR rates in patients with MTLE-HS.
[Mh] Termos MeSH primário: Anticonvulsivantes/uso terapêutico
Epilepsia do Lobo Temporal/tratamento farmacológico
Hipocampo/patologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Aminas/uso terapêutico
Ataxia/induzido quimicamente
Benzodiazepinas/uso terapêutico
Carbamazepina/análogos & derivados
Carbamazepina/uso terapêutico
Ácidos Cicloexanocarboxílicos/uso terapêutico
Bases de Dados Factuais
Diplopia/induzido quimicamente
Tontura/induzido quimicamente
Epilepsia do Lobo Temporal/patologia
Epilepsia do Lobo Temporal/fisiopatologia
Feminino
Frutose/análogos & derivados
Frutose/uso terapêutico
Seres Humanos
Letargia/induzido quimicamente
Masculino
Meia-Idade
Pregabalina/uso terapêutico
Estudos Retrospectivos
Esclerose
Resultado do Tratamento
Triazinas/uso terapêutico
Ácido Valproico/uso terapêutico
Vertigem/induzido quimicamente
Vigabatrina/uso terapêutico
Transtornos da Visão/induzido quimicamente
Adulto Jovem
Ácido gama-Aminobutírico/uso terapêutico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amines); 0 (Anticonvulsants); 0 (Cyclohexanecarboxylic Acids); 0 (Triazines); 0H73WJJ391 (topiramate); 12794-10-4 (Benzodiazepines); 2MRO291B4U (clobazam); 30237-26-4 (Fructose); 33CM23913M (Carbamazepine); 55JG375S6M (Pregabalin); 56-12-2 (gamma-Aminobutyric Acid); 614OI1Z5WI (Valproic Acid); 6CW7F3G59X (gabapentin); GR120KRT6K (Vigabatrin); U3H27498KS (lamotrigine); VZI5B1W380 (oxcarbazepine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170901
[St] Status:MEDLINE
[do] DOI:10.1111/epi.13871


  3 / 1530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28691157
[Au] Autor:Jackson MC; Jafarpour S; Klehm J; Thome-Souza S; Coughlin F; Kapur K; Loddenkemper T
[Ad] Endereço:Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, U.S.A.
[Ti] Título:Effect of vigabatrin on seizure control and safety profile in different subgroups of children with epilepsy.
[So] Source:Epilepsia;58(9):1575-1585, 2017 Sep.
[Is] ISSN:1528-1167
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the efficacy and safety of vigabatrin in pediatric epilepsy. METHODS: We retrospectively reviewed patients with epilepsy treated with vigabatrin over a 2-year period at a pediatric tertiary center. We assessed the relationship between seizure frequency, etiology, vigabatrin dose, adverse events, medication discontinuation reasons, and electroencephalography (EEG) characteristics. RESULTS: One hundred three patients followed at Boston Children's Hospital were treated with vigabatrin and had complete medical records. Within the follow-up interval, 69 (67%) of 103 patients had discontinued vigabatrin therapy. Two patients (1.9%) died during therapy for unknown reasons. Median age at vigabatrin initiation was 8 months (interquartile range [IQR] 5-15). Median starting dose was 48.1 mg/kg per day (IQR 29.8-52.3) with a median target of 100 mg/kg (IQR 81.9-107.9). Median treatment duration was 12.1 months (n = 89, IQR 5.0-22.9) overall, and 13.3 months (IQR 5.2-23.2) for patients who discontinued vigabatrin. The most common reasons for discontinuation were controlled seizures in 31 (43.7%) of 71 and unsatisfactory therapeutic effect in 23 (32.4%) of 71. Median percent seizure reduction from baseline to first follow-up was 83.3% (IQR 27.4-99.8) and 96.7% (IQR 43.3-100) to last follow-up. Twenty-four (38.7%) of 62 patients with a follow-up posttreatment remained seizure-free. Four patients who had initially achieved seizure freedom relapsed. Patients with structural/metabolic etiology had greater median percent seizure reduction at first follow-up than patients with genetic etiology (98.7% vs. 61.4%, respectively, p = 0.001). Hypsarrhythmia resolved after therapy in 18 of 20 (90%, 95% confidence interval [CI] 70-97) patients with pretreatment hypsarrhythmia, and 2 patients presented with hypsarrhythmia posttreatment. Risk of having hypsarrhythmia was reduced by 32% (95% CI 14.9-49.1) posttreatment. SIGNIFICANCE: Vigabatrin is efficacious in all seizure types and resolved hypsarrhythmia in most patients. In this series with a median treatment duration of 12.1 months, vigabatrin had a good safety profile with a low rate of discontinuation due to nonophthalmologic and ophthalmologic adverse effects.
[Mh] Termos MeSH primário: Anticonvulsivantes/uso terapêutico
Epilepsia/tratamento farmacológico
Convulsões/tratamento farmacológico
Vigabatrina/uso terapêutico
[Mh] Termos MeSH secundário: Anticonvulsivantes/efeitos adversos
Encéfalo/efeitos dos fármacos
Encéfalo/fisiopatologia
Eletroencefalografia
Feminino
Seres Humanos
Lactente
Masculino
Estudos Retrospectivos
Resultado do Tratamento
Vigabatrina/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticonvulsants); GR120KRT6K (Vigabatrin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170711
[St] Status:MEDLINE
[do] DOI:10.1111/epi.13836


  4 / 1530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28401986
[Au] Autor:Fosi T; Werner K; Boyd SG; De Haan M; Scott RC; Neville BG
[Ad] Endereço:Young Epilepsy, Surrey, United Kingdom.
[Ti] Título:Auditory processing following infantile spasms: An event-related potential study.
[So] Source:Epilepsia;58(5):872-881, 2017 May.
[Is] ISSN:1528-1167
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To investigate acoustic auditory processing in patients with recent infantile spasms (IS). METHODS: Patients (n = 22; 12 female; median age 8 months; range 5-11 months) had normal preceding development, brain magnetic resonance imaging (MRI), and neurometabolic testing (West syndrome of unknown cause, uWS). Controls were healthy babies (n = 22; 11 female; median age 6 months; range 3-12 months). Event-related potentials (ERPs) and psychometry (Bayley Scales of Infant Development, Second Edition, BSID-II) took place at a month following IS remission. RESULTS: Following a repeated pure tone, uWS patients showed less suppression of the N100 at the mid-temporal electrodes (p = 0.006), and a prolonged response latency (p = 0.019). Their novelty P300 amplitude over the mid-temporal electrodes was halved (p = 0.001). The peak of the novelty P300 to environmental broadband sounds emerged later over the left temporal lobe in patients (p = 0.015), the lag correlating with duration of spasms (r = 0.547, p = 0.015). BSID-II scores were lower in patients (p < 0.001), with no correlation to ERP. SIGNIFICANCE: Complex acoustic information is processed poorly following IS. This would impair language. Treatment did not reverse this phenomenon, but may have limited its severity. The data are most consistent with altered connectivity of the cortical acoustic processing areas induced by IS.
[Mh] Termos MeSH primário: Percepção Auditiva/fisiologia
Potenciais Evocados Auditivos/fisiologia
Espasmos Infantis/diagnóstico
Espasmos Infantis/fisiopatologia
[Mh] Termos MeSH secundário: Estimulação Acústica
Vias Auditivas/efeitos dos fármacos
Vias Auditivas/fisiopatologia
Percepção Auditiva/efeitos dos fármacos
Estudos de Casos e Controles
Córtex Cerebral/efeitos dos fármacos
Córtex Cerebral/fisiopatologia
Estudos Transversais
Eletroencefalografia
Potencial Evocado P300/efeitos dos fármacos
Potencial Evocado P300/fisiologia
Potenciais Evocados Auditivos/efeitos dos fármacos
Feminino
Seres Humanos
Lactente
Masculino
Prednisolona/uso terapêutico
Prognóstico
Estudos Prospectivos
Tempo de Reação/efeitos dos fármacos
Tempo de Reação/fisiologia
Processamento de Sinais Assistido por Computador
Espasmos Infantis/tratamento farmacológico
Lobo Temporal/efeitos dos fármacos
Lobo Temporal/fisiologia
Gravação em Vídeo
Vigabatrina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9PHQ9Y1OLM (Prednisolone); GR120KRT6K (Vigabatrin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170630
[Lr] Data última revisão:
170630
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170413
[St] Status:MEDLINE
[do] DOI:10.1111/epi.13725


  5 / 1530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28230253
[Au] Autor:Hussain SA; Tsao J; Li M; Schwarz MD; Zhou R; Wu JY; Salamon N; Sankar R
[Ad] Endereço:Division of Pediatric Neurology, David Geffen School of Medicine and Mattel Children's Hospital UCLA, Los Angeles, California, U.S.A.
[Ti] Título:Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent.
[So] Source:Epilepsia;58(4):674-682, 2017 Apr.
[Is] ISSN:1528-1167
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Although the link between vigabatrin (VGB) and retinotoxicity is well known, little attention has been focused on the risk of VGB-associated brain abnormalities on magnetic resonance imaging (MRI) (VABAM), namely reversible-and largely asymptomatic-signal changes in the thalami, basal ganglia, brainstem tegmentum, and cerebellar nuclei. Using a large infantile spasms cohort, we set out to identify predictors of these phenomena. METHODS: Children with infantile spasms were retrospectively identified. Brain MRI reports were serially reviewed without knowledge of VGB exposure. Upon VABAM discovery, records were systematically reviewed to ascertain presence of symptoms attributable to VGB. Separately, progress notes were sequentially reviewed to identify and quantify VGB exposure. RESULTS: We identified 507 brain MRI studies among 257 patients with infantile spasms. VGB treatment was documented in 143 children, with detailed exposure data available for 104, of whom 45 had at least one MRI study during VGB treatment. Among the limited subset of asymptomatic children who underwent MRI (n = 40), 6 exhibited VABAM. Risk of asymptomatic VABAM was dose-dependent, as peak (but not cumulative) VGB dosage was strongly associated with asymptomatic VABAM (p = 0.0028). In an exploratory analysis, we encountered 4 children with symptomatic VABAM among 104 patients with detailed VGB exposure data. Risk of symptomatic VABAM was seemingly dose-independent, and potentially associated with concomitant hormonal therapy (i.e., prednisolone and adrenocorticotropic hormone [ACTH]) (p = 0.039). SIGNIFICANCE: We have demonstrated dose-dependent risk of asymptomatic VABAM and uncovered a possible association between symptomatic VABAM and concomitant hormonal therapy. Caution should be exercised in the use of high VGB dosage (i.e., >175 mg/kg/day), and further study is warranted to confirm the potential impact of hormonal therapy.
[Mh] Termos MeSH primário: Anticonvulsivantes/efeitos adversos
Encéfalo/efeitos dos fármacos
Encéfalo/diagnóstico por imagem
Imagem por Ressonância Magnética
Espasmos Infantis/tratamento farmacológico
Vigabatrina/efeitos adversos
[Mh] Termos MeSH secundário: Pré-Escolar
Relação Dose-Resposta a Droga
Eletroencefalografia
Feminino
Seres Humanos
Processamento de Imagem Assistida por Computador
Lactente
Masculino
Estudos Retrospectivos
Espasmos Infantis/diagnóstico por imagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticonvulsants); GR120KRT6K (Vigabatrin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170626
[Lr] Data última revisão:
170626
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170224
[St] Status:MEDLINE
[do] DOI:10.1111/epi.13712


  6 / 1530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27866846
[Au] Autor:Zhao J; Shin Y; Jin Y; Jeong KM; Lee J
[Ad] Endereço:School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
[Ti] Título:Determination of enantiomeric vigabatrin by derivatization with diacetyl-l-tartaric anhydride followed by ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;1040:199-207, 2017 Jan 01.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Vigabatrin, one of the most widely used antiepileptic drugs, is marketed and administered as a racemic mixture, while only S-enantiomer is therapeutically effective. In the present study, diacetyl-l-tartaric acid anhydride was used as an inexpensive and effective chiral derivatization reagent to produce tartaric acid monoester derivatives of vigabatrin enantiomers that could be readily resolved by reversed phase chromatography. Derivatization conditions were statistically optimized by response surface methodology, resulting in an optimal reaction temperature of 44°C and an optimal reaction time of 30min. The derivatized diastereomers of vigabatrin and internal standard (gabapentin) were analyzed using ultra-high performance liquid chromatography coupled to quadrupole-time-of-flight mass spectrometry. For this analysis, an Agilent ZORBAX Rapid Resolution High Definition Eclipse Plus C18 column (100mm×2.1mm, 1.8µm) was employed for chromatographic separation using 10mM ammonium formate (pH 3.0) and methanol as mobile phase at a flow rate of 0.2mLmin . The established method was validated in terms of specificity, linearity, precision, accuracy, dilution integrity, recovery, matrix effect, stability, and incurred sample reanalysis. It was linear over a range of 0.25-100.0mgL for both S- and R-enantiomers (R ≥0.9987 for both). Intra- and inter-day precisions and accuracies were within acceptable ranges. The method was successfully applied to determine the levels of vigabatrin enantiomers in mouse serum after administration of vigabatrin racemate.
[Mh] Termos MeSH primário: Anticonvulsivantes/sangue
Cromatografia Líquida de Alta Pressão/métodos
Vigabatrina/sangue
[Mh] Termos MeSH secundário: Anidridos/química
Animais
Anticonvulsivantes/análise
Diacetil/química
Masculino
Espectrometria de Massas/métodos
Camundongos Endogâmicos ICR
Estereoisomerismo
Tartaratos/química
Vigabatrina/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Anhydrides); 0 (Anticonvulsants); 0 (Tartrates); GR120KRT6K (Vigabatrin); K324J5K4HM (Diacetyl); W4888I119H (tartaric acid)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170313
[Lr] Data última revisão:
170313
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161122
[St] Status:MEDLINE


  7 / 1530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27864823
[Au] Autor:Vogel KR; Ainslie GR; Pearl PL; Gibson KM
[Ad] Endereço:Division of Experimental and Systems Pharmacology, College of Pharmacy, Washington State University, Spokane, Washington, USA.
[Ti] Título:Aberrant mTOR signaling and disrupted autophagy: The missing link in potential vigabatrin-associated ocular toxicity?
[So] Source:Clin Pharmacol Ther;101(4):458-461, 2017 Apr.
[Is] ISSN:1532-6535
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Vigabatrin (VGB; γ-vinylGABA) is a unique antiepileptic directly elevating CNS GABA via inactivation of the GABA metabolic enzyme GABA-transaminase. VGB is effective in treating infantile spasms, a rare seizure disorder associated with significant morbidity. The potential for unexplained bilateral constriction of the visual field associated with VGB intervention can severely limit its temporal utility. Removal of this potential adverse effect with adjuvant intervention(s) would represent a significant advance in epilepsy therapeutics.
[Mh] Termos MeSH primário: Anticonvulsivantes/efeitos adversos
Autofagia/efeitos dos fármacos
Serina-Treonina Quinases TOR/efeitos dos fármacos
Vigabatrina/efeitos adversos
Transtornos da Visão/induzido quimicamente
[Mh] Termos MeSH secundário: Potenciais Evocados Visuais
Seres Humanos
Lactente
Recém-Nascido
Transdução de Sinais
Espasmos Infantis
Transtornos da Visão/fisiopatologia
Ácido gama-Aminobutírico/biossíntese
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticonvulsants); 56-12-2 (gamma-Aminobutyric Acid); EC 2.7.1.1 (MTOR protein, human); EC 2.7.1.1 (TOR Serine-Threonine Kinases); GR120KRT6K (Vigabatrin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170516
[Lr] Data última revisão:
170516
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161120
[St] Status:MEDLINE
[do] DOI:10.1002/cpt.581


  8 / 1530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27838190
[Au] Autor:O'Callaghan FJ; Edwards SW; Alber FD; Hancock E; Johnson AL; Kennedy CR; Likeman M; Lux AL; Mackay M; Mallick AA; Newton RW; Nolan M; Pressler R; Rating D; Schmitt B; Verity CM; Osborne JP; participating investigators
[Ad] Endereço:Institute of Child Health, University College London, London, UK; Children's Department, Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath, UK. Electronic address: f.o'callaghan@ucl.ac.uk.
[Ti] Título:Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial.
[So] Source:Lancet Neurol;16(1):33-42, 2017 Jan.
[Is] ISSN:1474-4465
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Infantile spasms constitutes a severe infantile epilepsy syndrome that is difficult to treat and has a high morbidity. Hormonal therapies or vigabatrin are the most commonly used treatments. We aimed to assess whether combining the treatments would be more effective than hormonal therapy alone. METHODS: In this multicentre, open-label randomised trial, 102 hospitals (Australia [three], Germany [11], New Zealand [two], Switzerland [three], and the UK [83]) enrolled infants who had a clinical diagnosis of infantile spasms and a hypsarrhythmic (or similar) EEG no more than 7 days before enrolment. Participants were randomly assigned (1:1) by a secure website to receive hormonal therapy with vigabatrin or hormonal therapy alone. If parents consented, there was an additional randomisation (1:1) of type of hormonal therapy used (prednisolone or tetracosactide depot). Block randomisation was stratified for hormonal treatment and risk of developmental impairment. Parents and clinicians were not masked to therapy, but investigators assessing electro-clinical outcome were masked to treatment allocation. Minimum doses were prednisolone 10 mg four times a day or intramuscular tetracosactide depot 0·5 mg (40 IU) on alternate days with or without vigabatrin 100 mg/kg per day. The primary outcome was cessation of spasms, which was defined as no witnessed spasms on and between day 14 and day 42 from trial entry, as recorded by parents and carers in a seizure diary. Analysis was by intention to treat. The trial is registered with The International Standard Randomised Controlled Trial Number (ISRCTN), number 54363174, and the European Union Drug Regulating Authorities Clinical Trials (EUDRACT), number 2006-000788-27. FINDINGS: Between March 7, 2007, and May 22, 2014, 766 infants were screened and, of those, 377 were randomly assigned to hormonal therapy with vigabatrin (186) or hormonal therapy alone (191). All 377 infants were assessed for the primary outcome. Between days 14 and 42 inclusive no spasms were witnessed in 133 (72%) of 186 patients on hormonal therapy with vigabatrin compared with 108 (57%) of 191 patients on hormonal therapy alone (difference 15·0%, 95% CI 5·1-24·9, p=0·002). Serious adverse reactions necessitating hospitalisation occurred in 33 infants (16 on hormonal therapy alone and 17 on hormonal therapy with vigabatrin). The most common serious adverse reaction was infection occurring in five infants on hormonal therapy alone and four on hormonal therapy with vigabatrin. There were no deaths attributable to treatment. INTERPRETATION: Hormonal therapy with vigabatrin is significantly more effective at stopping infantile spasms than hormonal therapy alone. The 4 week period of spasm cessation required to achieve a primary clinical response to treatment suggests that the effect seen might be sustained, but this needs to be confirmed at the 18 month follow-up. FUNDING: The Castang Foundation, Bath Unit for Research in Paediatrics, National Institute of Health Research, the Royal United Hospitals Bath NHS Foundation Trust, the BRONNER-BENDUNG Stifung/Gernsbach, and University Children's Hospital Zurich.
[Mh] Termos MeSH primário: Anticonvulsivantes/uso terapêutico
Hormônios/uso terapêutico
Espasmos Infantis/tratamento farmacológico
Resultado do Tratamento
Vigabatrina/uso terapêutico
[Mh] Termos MeSH secundário: Cosintropina/uso terapêutico
Esquema de Medicação
Quimioterapia Combinada
Eletroencefalografia
Feminino
Seguimentos
Seres Humanos
Lactente
Masculino
Prednisolona/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anticonvulsants); 0 (Hormones); 16960-16-0 (Cosyntropin); 9PHQ9Y1OLM (Prednisolone); GR120KRT6K (Vigabatrin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170526
[Lr] Data última revisão:
170526
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161114
[St] Status:MEDLINE


  9 / 1530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27552291
[Au] Autor:Wright T; Kumarappah A; Stavropoulos A; Reginald A; Buncic JR; Westall CA
[Ad] Endereço:*Department of Ophthalmology and Vision Science, The Hospital for Sick Children, Toronto, Ontario, Canada; and †University of Toronto, Toronto, Ontario, Canada.
[Ti] Título:VIGABATRIN TOXICITY IN INFANCY IS ASSOCIATED WITH RETINAL DEFECT IN ADOLESCENCE: A Prospective Observational Study.
[So] Source:Retina;37(5):858-866, 2017 May.
[Is] ISSN:1539-2864
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The purpose was to determine whether vigabatrin (VGB) (Sabril)-attributed retinal toxicity defined by electroretinogram in early childhood is associated with visual system defect in adolescents after discontinuation of VGB. METHODS: This prospective cross-sectional study included 24 children previously treated with VGB and monitored in early childhood by electroretinogram for VGB-attributed retinal defects. Ten had been diagnosed with VGB-attributed retinal defect (Group I) and 14 had no VGB-attributed retinal defect (Group II). Outcome measures were extent of monocular visual fields using Goldmann kinetic perimetry and RNFL thickness at the optic nerve head, using optical coherence tomography. RESULTS: Of those able to complete testing (6 eyes Group I and 16 eyes Group II), Goldmann results revealed results of visual field loss in Group I and not in Group II. The optical coherence tomography results demonstrated attenuation of the RNFL in all 6 eyes of Group I participants and in only 1 eye of 10 Group II participants. Optical coherence tomography data were nonoverlapping between Group 1 and Group II eyes. CONCLUSION: The VGB-attributed retinal toxicity identified by means of electroretinogram in infancy was associated with visual field loss and RNFL attenuation of the retinal nerve when tested in adolescence.
[Mh] Termos MeSH primário: Anticonvulsivantes/efeitos adversos
Retina/efeitos dos fármacos
Doenças Retinianas/induzido quimicamente
Vigabatrina/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Criança
Estudos Transversais
Eletrorretinografia
Feminino
Seres Humanos
Masculino
Disco Óptico/patologia
Estudos Prospectivos
Doenças Retinianas/patologia
Doenças Retinianas/fisiopatologia
Campos Visuais/fisiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Anticonvulsants); GR120KRT6K (Vigabatrin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160824
[St] Status:MEDLINE
[do] DOI:10.1097/IAE.0000000000001246


  10 / 1530 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27941319
[Au] Autor:Tao Y; Yang J; Ma Z; Yan Z; Liu C; Ma J; Wang Y; Yang Z; Huang YF
[Ad] Endereço:Department of Ophthalmology, General Hospital of Chinese PLA, Beijing, P.R. China.
[Ti] Título:The Vigabatrin Induced Retinal Toxicity is Associated with Photopic Exposure and Taurine Deficiency: An In Vivo Study.
[So] Source:Cell Physiol Biochem;40(5):831-846, 2016.
[Is] ISSN:1421-9778
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIMS: Retinal toxicity is one of the most commonly discussed and concerning adverse effects of vigabatrin (VGB). The present study explored the relationship between the VGB elicited retinal toxicity, photopic exposure, and taurine deficiency, aiming at screening for risk factors to minimize the adverse effects of VGB. METHODS: The effects of VGB on function and morphology of mouse retinas were examined via a series of in vivo tests, including electroretinography (ERG), Spectral domain optical coherence tomography (SD-OCT), and optokinetic testing. Moreover, VGB-treated mice were in addition treated with taurine to verify possible protective effects against retinal toxicity. RESULTS: A close relationship between VGB induced retinal toxicity and light exposure was observed. The VGB-treated mice which were reared in darkness preserved better visual function and retinal architectures as verified by the optokinetic tests, OCT and ERG examinations. The retinal taurine level of the VBG-treated mice which were exposed to light were significantly lower than that of the VBG mice reared in darkness. Furthermore, several in vivo evidence provided by our research confirmed that the VGB induced morphological and functional impairments could be partially alleviated by taurine treatment. The present study showed the retinal toxicity of VGB by in vivo measurements. CONCLUSION: The VGB induced retinal toxicity is closely associated with photopic exposure and taurine deficiency. Patients who are taking VGB might benefit from minimization of light exposure and dietetic taurine supplements.
[Mh] Termos MeSH primário: Luz
Retina/patologia
Retina/efeitos da radiação
Taurina/deficiência
Vigabatrina/efeitos adversos
[Mh] Termos MeSH secundário: Animais
Eletrorretinografia
Camundongos Endogâmicos C57BL
Fatores de Tempo
Tomografia de Coerência Óptica
Vigabatrina/administração & dosagem
Acuidade Visual/efeitos dos fármacos
Acuidade Visual/efeitos da radiação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
1EQV5MLY3D (Taurine); GR120KRT6K (Vigabatrin)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170206
[Lr] Data última revisão:
170206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161213
[St] Status:MEDLINE



página 1 de 153 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde